Introgen Invites You to Join Its Fourth Quarter Conference Call on the Web.

AUSTIN, Texas, Aug. 1 /PRNewswire/ --

Introgen Therapeutics, Inc. (Nasdaq: INGN), in conjunction with its fourth quarter financial results for the fiscal year ended June 30, 2001, invites you to listen to its conference call that will be broadcast live over the Internet on August 7, 2001 at 4:30 p.m. EDT with David Nance, president and chief executive officer, Jim Albrecht, chief financial officer, James Merritt, M.D., vice president of clinical affairs, and Tom Finnegan, vice president of finance.

What: Introgen Therapeutics quarterly earnings conference call

When: August 7, 2001, 4:30 p.m. EDT

Where: http://www.videonewswire.com/event.asp?id=627

How: Live over the Internet -- Simply log on to the Web at the

address listed above or access through Introgen's Website

Contact: Channing Burke, Introgen Therapeutics, 512-708-9310, Ext. 322

Introgen is a leader in the development and production of gene-based drugs for the treatment of cancer and other diseases. Introgen's product candidates engage precise molecular targets to produce a highly specific therapeutic effect. Introgen specializes in combining appropriate gene delivery systems and therapeutic genes to make its gene-based drugs. Introgen's lead product candidate, INGN 201, is currently in Phase III clinical trials for the treatment of head and neck cancer. INGN 201 has been used in numerous clinical trials worldwide either alone or in combination with conventional treatments such as chemotherapy and radiotherapy. Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer. In an announcement earlier this year, Introgen published results of preclinical studies which indicate a possible application of INGN 201 whereby the human immune system may be directed to attack tumor cells. Introgen's second product candidate, INGN 241 (Adenoviral-mda7), for the treatment of solid tumors, is in Phase I clinical development. Introgen controls a broad intellectual property portfolio that includes more than 200 pending and issued patents for a variety of gene therapy technologies. Introgen owns a fully staffed and validated Good Manufacturing Practices (cGMP) production facility that is producing Phase III and commercial inventory of INGN 201. Introgen has received a U.S. patent for the commercial scale production of adenovirus.

If you are unable to participate during the live web cast, the call will be archived for 30 days at: http://www.videonewswire.com/event.asp?id=627 or at http://www.introgen.com in the Investor Relations section.

Minimum Requirements to listen to broadcast: The WindowsMedia Player software, downloadable free from http://www.microsoft/com/windows/windowsmedia/EN/default.asp , and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to isproducers@prnewswire.com.

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X36342266